Connoya Biomedical

Keymed Biosciences, also known as Connoya Biomedical, is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative biological therapies for autoimmune and oncology indications. Headquartered in Chengdu, China, the company utilizes its proprietary nTCE bispecific antibody platform and high-throughput screening technologies to build a differentiated pipeline. Its lead candidate, Stapokibart (CM310), is a humanized monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα) that is currently under NDA review in China for atopic dermatitis. Keymed has established significant global collaborations, most notably a licensing agreement with AstraZeneca for CMG901, a first-in-class Claudin 18.2-targeting antibody-drug conjugate. The company's pipeline also includes several bispecific antibodies and monoclonal antibodies targeting TSLP, CD38, and BCMA. With its own large-scale GMP manufacturing facilities, Keymed is strategically positioned to transition from a research-focused biotech to a fully integrated commercial-stage biopharmaceutical enterprise.